Index of drugs

Short-term treatment of the symptoms of gastroesophageal reflux disease (eg heartburn, regurgitation of stomach contents) in adults.

1 tabl enteric contains 20 mg of pantoprazole.

Proton pump inhibitor. Pantoprazole is a substituted benzoimidazole that inhibits the secretion of hydrochloric acid in the stomach by specifically blocking the proton pump of parietal cells. In an acidic environment, in the lumen of the parietal cells, pantoprazole is converted to the active form where it inhibits the H enzyme⁺, K⁺-ATPase, i.e. the last step in the production of hydrochloric acid in the stomach. This inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, the symptoms disappear within a week. Treatment with pantoprazole increases the amount of gastrin in proportion to the reduction in gastric acidity. The increase in gastrin secretion is reversible. Pantoprazole can affect the secretion of hydrochloric acid independently of stimulation by other substances (acetylcholine, histamine, gastrin). The drug is quickly and completely absorbed from the digestive tract. C_max in serum, it is about 2-2.5 hours after administration. Bioavailability is about 77%. Pantoprazole binds to plasma proteins in about 98%. Metabolized almost exclusively in the liver. T_0,5 It is about 1 hour. Metabolites of pantoprazole are mainly excreted by the kidneys (about 80%), the remainder is excreted in the faeces. The main metabolite in both plasma and urine is demethyl Pantoprazole, which is conjugated to sulfate. T_0,5 the main metabolite is about 1.5 hours.

Hypersensitivity to the active substance or to any of the excipients. Co-administration with atazanavir.

The patient should be advised to contact a physician if: losing weight without intentional weight loss, anemia, gastrointestinal bleeding, dysphagia, persistent or vomiting with blood (treatment with pantoprazole may relieve the symptoms of severe disease and delay its diagnosis, in these cases it is necessary to exclude cancerous background of the disease); history of gastric ulcer or surgery in the gastrointestinal tract; treating the symptoms of indigestion or heartburn lasting for more than 4 weeks; jaundice, liver dysfunction or disease; other severe diseases affecting general well-being; if he is> 55 years of age and has had new symptoms or has changed the nature of previously observed symptoms. Patients with long-term recurrent symptoms of indigestion or heartburn should undergo regular medical check-ups, in particular patients> 55 years of age. Do not use other proton pump inhibitors or histamine H receptor antagonists₂. Patients who are to undergo endoscopy or urease respiratory tests should consult a physician before using this product. Patients should be advised that the preparation is not intended for the immediate removal of symptoms. Symptom relief may be felt after about the age of pantoprazole, and it may be necessary for 7 days to achieve complete resolution of heartburn. Pantoprazole should not be used prophylactically. Reducing the acidity of gastric juice, for any reason - also as a result of using proton pump inhibitors, increases the amount of bacteria normally present in the gastrointestinal tract. The use of drugs that reduce gastric acid secretion leads to a slightly higher risk of gastrointestinal infections, such as infectionSalmonella, CampylobacterorC. difficile.It should not be used in children and adolescents <18 years.

The product should not be used during pregnancy and breast-feeding.

Uncommon: pain and dizziness, diarrhea, nausea, vomiting, abdominal fullness and bloating, constipation, dry mouth, epigastric pain and discomfort, skin rash, erythema, skin eruptions, pruritus, weakness, fatigue, bad mood, increased activity of liver enzymes (aminotransferases, γ-GT), sleep disorders.Rare: agranulocytosis, blurred vision / blurred vision, urticaria, angioneurotic edema, joint pain, myalgia, hyperlipidemia and increased lipids (triglycerides, cholesterol), weight change, gynecomastia, elevated body temperature, peripheral edema, hypersensitivity reactions (including anaphylactic reactions and anaphylactic shock), increased bilirubin, depression and deterioration of the mental state, dysgeusia. Very rare: thrombocytopenia, leukopenia, pancytopenia, confusion (and mental deterioration). Not known: interstitial nephritis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, photosensitivity, hyponatremia, hypomagnesaemia, liver cell damage, jaundice, hepatic cell failure, hallucinations, confusion (especially susceptible patients, as well as the severity of similar symptoms in the event of their previous occurrence).

Orally. Adults: 1 tabl. once a day. In order to achieve relief of symptoms, it may be necessary to use the medicine for another 2-3 days. After complete relief of symptoms, treatment should be discontinued. The drug should not be used for more than 4 weeks without consulting your doctor. Patients should be advised to consult a doctor if symptoms persist within 2 weeks of treatment. Elderly patients with renal or hepatic impairment do not need to modify their dosage. The tablets should not be chewed and chewed; take before meals, swallowing whole and washed down with water.